Biohaven eyes mid-2021 for migraine prevention drug launch

"I hope that in 6 months or so from now that we will be the first oral CGRP with the indication for the prevention of migraine," Biohaven CEO Vlad Coric said.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.